Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Malaria | Research

Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals

Authors: M. Bonsergent, M. Tching-Sin, S. Honoré, P. Bertault-Peres, A. Lepelletier, L. Flet, T. Perez

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Intravenous artesunate (AS) is the first-line treatment for patients with severe imported malaria (SIM) worldwide. However, after 10 years of use in France, AS hasn’t yet received marketing authorization.The purpose of this study was to assess the real-life effectiveness and safety of AS in the treatment of SIM in two Hospitals in France.

Methods

We performed a bicenter retrospective and observational study. All patients treated with AS for SIM between 2014 and 2018 and 2016–2020 were included. The effectiveness of AS was evaluated by parasite clearance, number of deaths, and the length of hospital stay. The real-life safety was assessed by related adverse events (AE) and monitoring of biological blood parameters during the hospital stay and follow-up period.

Results

110 patients were included during the six-year study period. 71.8% of patients were parasite-negative of their day 3 thick and thin blood smears after AS treatment. No patients discontinued AS due to an AE and no serious AE were declared. Two cases of delayed post-artesunate hemolysis occurred and required blood transfusions.

Conclusion

This study highlights effectiveness and safety of AS in non-endemic areas. Administrative procedures must be accelerated in order to obtain full registration and facilitate access to AS in France.
Literature
1.
2.
3.
4.
Dondorp A, Nosten F, Stepniewska K et al. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet Lond Engl 2005 Sep 27;366(9487):717–25.
5.
Dondorp AM, Fanello CI, Hendriksen ICE et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet Lond Engl 2010 Nov 13;376(9753):1647–57.
6.
Udomsangpetch R, Pipitaporn B, Krishna S, et al. Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis. 1996 Mar;173(3):691–8.
7.
Sinclair D, Donegan S, Isba R et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012 Jun 13;2012(6).
8.
Mørch K, Strand Ø, Dunlop O et al. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis 2008 Nov;14(11):1816–8.
9.
Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011 May;17(5):771–7.
10.
Kurth F, Develoux M, Mechain M, et al. Severe malaria in Europe: an 8-year multi-centre observational study. Malar J. 2017;31(1):57.CrossRef
11.
12.
13.
14.
15.
Marks ME, Armstrong M, Suvari MM, et al. Severe imported falciparum malaria among adults requiring intensive care: a retrospective study at the hospital for tropical diseases, London. BMC Infect Dis. 2013 Mar;5:13:118.
16.
Kurth F, Zoller T. Reply to Jaureguiberry. Clin Infect Dis Off Publ Infect Dis Soc Am 2016 Jan 15;62(2):271.
17.
Checkley AM, Smith A, Smith V, et al. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012 Mar;27:344:e2116.
18.
Santos LC, Abreu CF, Xerinda SM, et al. Severe imported malaria in an intensive care unit: a review of 59 cases. Malar J. 2012 Mar;29:11:96.
19.
Seringe E, Thellier M, Fontanet A, et al. Severe imported Plasmodium falciparum malaria, France, 1996–2003. Emerg Infect Dis. 2011 May;17(5):807–13.
20.
Roussel C, Caumes E, Thellier M et al. Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications. J Travel Med. 2017 Mar 1;24(2).
21.
Jauréguiberry S, Thellier M, Ndour PA, et al. Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011–2013. Emerg Infect Dis. 2015 May;21(5):804–12.
22.
Kurth F, Develoux M, Mechain M et al. Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 Nov 1;61(9):1441–4.
23.
Eder M, Farne H, Cargill T, et al. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Glob Health. 2012 Jul;106(3):181–7.
24.
El Ket N, Kendjo E, Thellier M, et al. Propensity score analysis of Artesunate Versus quinine for severe Imported Plasmodium falciparum Malaria in France. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;02(2):280–7.CrossRef
25.
26.
Rolling T, Wichmann D, Schmiedel S, et al. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013 Jul;15:12:241.
27.
Arguin PM. Case definition: postartemisinin delayed hemolysis. Blood 2014 Jul 10;124(2):157–8.
28.
Itoda I, Yasunami T, Kikuchi K, et al. [Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate]. Kansenshogaku Zasshi. 2002 Aug;76(8):600–3.
29.
Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012 Mar;31:11:102.
30.
Rolling T, Agbenyega T, Krishna S, et al. Delayed haemolysis after artesunate treatment of severe malaria - review of the literature and perspective. Travel Med Infect Dis. 2015 Apr;13(2):143–9.
31.
Rehman K, Lötsch F, Kremsner PG, et al. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2014 Dec;29:268–73.
32.
33.
Seguro AC, Campos SB. Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg. 2002 Nov;67(5):473–4.
Metadata
Title
Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals
Authors
M. Bonsergent
M. Tching-Sin
S. Honoré
P. Bertault-Peres
A. Lepelletier
L. Flet
T. Perez
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Malaria
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08260-6

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue

Case Report

Case report: a case report and literature analysis on intestinal tuberculosis intestinal perforation complicated by umbilical intestinal fistula and bladder ileal fistula

Research

High incidence of fosfomycin-resistant uropathogenic E. coli among children

Case Report

Luteibacter jiangsuensis blood stream infection: a first case report

Research

Accuracy of saliva for SARS-CoV-2 detection in outpatients and their household contacts during the circulation of the Omicron variant of concern

Research article

Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey

Research

Pooling sputum testing to diagnose tuberculosis using xpert MTB/RIF and xpert ultra: a cost-effectiveness analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits